Studies on mutational signatures, such as those related to homologous recombination repair defects (9–12), mismatch repair defects (13, 14), and AID/APOBEC mutagenesis (15–17), have significant implications for the progress of precision medicine and immunotherapy in cancer. Here, AICDA is linked to cancer.